BTTX — Better Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
U.S. STOCKS ON THE MOVE-Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals
U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene
U.S. STOCKS ON THE MOVE-Cisco Systems, Inspired Entertainment, Spirit Airlines
U.S. STOCKS ON THE MOVE-G-III Apparel Group, Tesla, MicroStrategy
U.S. STOCKS ON THE MOVE-Robinhood Markets, ADM, Vaalco Energy
Better Therapeutics tumbles 81% on plans to wind down operations
Brief: Better Therapeutics Announces It Will Seek Strategic Alternatives And Will Be Delisted From Nasdaq
Brief: Better Therapeutics Announces Acceptance of Late Breaking Abstract For Its AspyreRx Pivotal Trial 180 Day Outcomes
Brief: Better Therapeutics Receives FDA Breakthrough Device Designation For Digital Therapeutic Platform
Brief: Better Therapeutics Signs Rebate Agreement With One Of The Largest Pharmacy Benefit Managers In The Us For Its Aspyrerx Diabetes Treatment
Brief: Better Therapeutics On Jan 5, Entered Into Securities Purchase Deal With David Perry, For Private Placement Of 1.47 Mln Shares Of Co's Common Stock
Brief: Better Therapeutics Files Prospectus Relates To Potential Offer
Brief: Better Therapeutics Strengthens Financial Position Through Amendment To Debt Facility And Implementation Of Cost Reductions
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork
Brief: Better Therapeutics Announces Launch Of Aspyrerxtm To Treat Adults With Type 2 Diabetes
U.S. STOCKS ON THE MOVE-Tempest Therapeutics, Ally Financial, Phio Pharmaceuticals
U.S. STOCKS ON THE MOVE-Myriad Genetics, Arista Networks, DaVita
Better Therapeutics gains on additional data from diabetes treatment application
Brief: Better Therapeutics Announces New Data Highlighting Concurrent Use Of Aspyrerx And Glp-1 Receptor Agonists To Treat Type 2 Diabetes